Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-7172 in advanced solid tumors with RAS mutations or amplifications
NCT07142980Phase 1Recruiting
- Sponsor
- Hengrui
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-7172 in solid tumor (advanced stage), sponsored by Hengrui. Primary endpoints: Adverse Events, Serious Adverse Events and 3 more. Started Sep 2025; status: recruiting.
02
Drugs
HRS-7172
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07142980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142980.